March 29, 2024
Frexalimab and CD40L Inhibition in Multiple Sclerosis
A phase II trial confirms the efficacy and safety of frexalimab and its ability to reduce disease activity in patients living with relapsing MS, with considerable benefit compared to placebo. The CD40–CD40L (CD154) costimulatory pathway, which regulates adaptive and innate immune responses, has been implicated in the pathogenesis of multiple sclerosis (MS). Elevated levels of...
Efficacy of Stem Cells vs. Exomes in Multiple Sclerosis
A new preclinical study in an animal model found that stem cells and stem cell-derived exosomes may benefit those living with multiple sclerosis. The study found exomes as a promising emerging therapy with a better safety profile. Multiple sclerosis (MS) is a debilitating autoimmune disease characterized by the progressive destruction of myelin. This demyelination leads...